Prostate cancer is one of the most commonly diagnosed cancers and a pressing health challenge in men worldwide. Radiation therapy (RT) is widely considered a standard therapy for advanced as well as localized prostate cancer. Although this primary therapy is associated with high cancer control rates, up to one-third of patients undergoing radiation therapy becomes radio-resistant and/or has tumor-relapse/recurrence. Therefore, focus on new molecular targets and pathways is essential to develop novel radio-sensitizing agents for the effective and safe treatment of prostate cancer. Here, we describe functional studies that were performed to investigate the role of structural maintenance of chromosome-1 (SMC1A) in radioresistance of metastatic prostate cancer cells. Short hairpin RNA (shRNA) was used to suppress SMC1A in metastatic castration-resistant prostate cancer cells, DU145 and PC3. Clonogenic survival assays, Western blot, RT-PCR, and γ-H2AX staining were used to assess the effect of SMC1A knockdown on radiation sensitivity of these prostate cancer cells. We demonstrate that SMC1A is overexpressed in human prostate tumors compared to the normal adjacent tissue. SMC1A knockdown limits the clonogenic potential, epithelial-mesenchymal transition (EMT), and cancer stem-like cell (CSC) properties of DU145 and PC3 cells and enhanced efficacy of RT in these cells. Targeted inhibition of SMC1A not only plays a critical role in overcoming radio-resistance in prostate cancer cells, but also suppresses self-renewal and the tumor-propagating potential of x-irradiated cancer cells. We propose that SMC1A could be a potential molecular target for the development of novel radio-sensitizing therapeutic agents for management of radio-resistant metastatic prostate cancer.
also projected that about 29 430 deaths due to the metastatic disease could be recorded. 1 While localized prostate cancer can be controlled with surgery and hormonal therapy, the metastatic, castrationresistant (mCRPC) disease remains a major treatment challenge. 2, 3 Currently available treatment options include administration of androgen receptor inhibitor (enzalutamide, abiraterone), cell cycle disruption (docetaxel, cabazitaxel), immune checkpoint-related therapy (sipuleucel-T), targeting of bone metastasis (radium-223), and radiotherapy. [4] [5] [6] [7] [8] Radiation therapy (RT) is widely considered a standard care treatment for primary and metastatic prostate cancer and is associated with high cancer control rates, although up to onethird of patients receiving this therapy becomes radio-resistant or manifest tumor-recurrence. [8] [9] [10] Radiotherapy kills the cancer cells directly by causing DNA damage, but radiation also causes the generation of reactive oxygen species (ROS) which are indirectly involved in DNA damage. [11] [12] [13] Moreover, RT promotes metastasis and invasion of cancer cells and is involved in epithelial-mesenchymal transition (EMT). [14] [15] [16] [17] [18] Therefore, attenuating EMT pathways may improve the efficacy of radiotherapy. Unfortunately, currently known anti-metastatic or anti-angiogenic inhibitors have limitations because of their acute toxicity and drug resistance. [15] [16] [17] [18] Here, we describe that structural maintenance of chromosome-1 (SMC1A), a member of cohesin and one of the major target substrates of ATM kinase is overexpressed in prostate cancer. It is also known to be overexpressed and associated with tumor metastasis in breast, lung, glioma, and colorectal cancers. [19] [20] [21] [22] Recently, its role has been highlighted in cell proliferation and maintenance of pluripotency. [23] [24] [25] Interestingly, SMC1A silencing attenuates the activation of Erk1/2 and Akt, which could be related to tumor metastasis and drug resistance. 22, 26, 27 SMC1A binds with breast cancer type 1 susceptibility protein (BRCA1), and together they are involved in the regulation of DNA-damage response and cell cycle checkpoint-mediated DNArepair in response to x-irradiation and chemotherapeutic agents. 28, 29 SMC1A phosphorylation is considered as a good prognostic marker for the efficacy of radiotherapy in hematological malignancies. 30 However, the role of SMC1A in sensitizing prostate cancer cells toward radiation therapy has not been explored yet.
In this study, we describe a key role of SMC1A in tumor-metastasis and resistance to radiation therapy. We dissected the role of SMC1A
in the association of cancer stem-like cells (CSCs), EMT, and DNAdamage response (DDR) pathways. We demonstrate that suppression of SMC1A expression reduces the self-renewal capacity of prostate cancer cells. Our results showed that SMC1A-suppression interferes with the progression of EMT and DDR pathway activation. More significantly, it works synergistically with radiation treatment to kill prostate cancer cells which express an augmented level of SMC1A.
| MATERIALS AND METHODS

| Reagents
Details of primary/secondary antibodies, shRNA, and sequence of primers used in this study are listed in Supplementary Tables S1 and S2 .
Commercially available prostate tissue microarrays (TMAs) were purchased from US Biomax (Rockville, MD). pLKO. 
| SMC1A knockdown
293T cells (purchased from ATCC) were grown in standard culture conditions and transfected by calcium phosphate co-precipitation with either pLKO.1-SMC1A shRNA1 or pLKO.1-non-silencing shRNA and the lentiviral packaging plasmids (pMDLg/pRRE, pRSV-Rev, pMD2.G).
The culture medium was replaced with fresh medium after 5 h and the supernatant was collected at 24 and 48 h. Prostate cancer cells (DU145 and PC3) were transduced with the viral vectors in the presence of 4 µg/mL polybrene. The transduced cells were selected with puromycin (1 µg/mL) and used for further experiments.
| Quantitative real time RT-PCR and Western blot
The expression of genes involved in EMT and maintenance of CSCs were quantified by real time qRT-PCR using gene-specific primers (Supplementary Table S1 ). Briefly, total RNA was isolated using the Direct-zol RNA miniprep kit and reverse transcribed using the Tetro cDNA synthesis kit following manufactures directions. qPCR was performed using a CFX96 touch real-time detection system (Bio-Rad, Hercules, CA). Relative mRNA expression was calculated using the comparative method where expression of the target genes in each sample was normalized to GAPDH expression.
The expression of proteins was detected by Western blot analysis. Appropriate amounts of lysates (∼20 μg protein) were resolved over Criterion™ TGX precast gels and then transferred onto polyvinylidenedifluoride (PDVF) membrane. The blots were blocked using 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 2 h at room temperature and probed using appropriate primary antibodies in 5% bovine serum albumin (BSA) in TBST buffer for overnight at 4°C. The detail of antibodies is given in Supplementary Table S2 . The membranes were then incubated with horseradish peroxidase (HRP) conjugated secondary antibody followed by detection using chemiluminescence ECL kit (Bio-Rad).
Densitometry measurements of the bands in Western blot were performed using GS-900 calibrated densitometer (Bio-Rad).
2.5 | Expression and cellular localization of SMC1A in prostate cancer cells Briefly, slides were deparaffinized using a sequential method of rehydration followed by antigen retrieval in citrate buffer with heating and then quenching in 3% hydrogen peroxide. Slides were blocked for 5 min using protein block (from Agilent Dako) and incubated with anti-SMC1A antibody (from Bethyl Labs; 1:500 dilution) overnight at 4°C. 
| Quantification of γH2AX foci formation after irradiation
NT and SMC1A shRNA expressing DU145 and PC3 cells were subjected to immunocytochemistry (ICC) to quantify γH2AX foci (DNA DSB marker) as described previously. 19, 32 Briefly, 20 000 cells/well were grown in 1.5 polymer tissue culture treated μ-slides with 8-well (Ibidi) and after 24 h, exposed to 2 Gy radiation. At specific time points (pre-radiation, 0.5, 2, 12, and 24 h after 2 Gy), medium was aspirated and cells were fixed with ice-cold methanol, acetic acid ( 
| ROS measurement
Cellular ROS was measured using 2′,7′-dichlorofluorescein diacetate (DCF-DA), a fluorogenic dye that measures hydroxyl, peroxyl, and other ROS activity within the cell as described. 35 Briefly, NT and 
| Cellular glutathione measurement
Cellular concentrations of glutathione (GSH) were measured using GSH-Glo™ assay kit following manufacturer's directions. Briefly, DU145 and PC3 and their corresponding SMC1A knockdown (SMC1A-shRNA) cells were seeded in 96-well plates (10 000 cells/ well) and grown in standard culture conditions overnight and irradiated on X-RAD SmART X-ray machine (225keV) at 2 Gy as described above.
In parallel, equal number of cells were plated and grown as a control (no radiation treatment). Two hours after radiation, culture medium was removed and 100 µL of 1× GSH-Glo™ reagent was added to each well and were incubated at room temperature for 30 min. Reconstituted luciferin detection reagent (100 µL) was added to each well, mixed on a plate shaker and incubated for 15 min. Luminescence was measured on microplate luminometer (Turner Biosystems). The ratio of cellular GSH concentration was calculated by control untreated versus radiation treated cells at different time points.
| Statistical analyses
All data were presented as the mean ± SD. We evaluated significance of differences between control and treatment groups using a twotailed unpaired Student's t-test. Differences were considered statistically significant when the P-value was less than 0.05. All statistical analysis was carried out in the freely downloadable software R (http:// cran.r-project.org/). showing the extra-nuclear localization and function of SMC1A in triple negative breast cancer (TNBC). 19 Considering that SMC1A expression was much higher in androgen-independent prostate derived human cancer cells DU145 and PC3, these cells were used for further defining its role in prostate cancer. Expression of SMC1A was also tested in TMAs by immunohistochemistry. SMC1A was found to be significantly Figure 1E ; P < 0.05). Table S3 ). In addition, sphere sizes were smaller in SMC1A shRNA expressing DU145 and PC3 cells ( Figures 5D and 5E ). These results suggest that silencing of SMC1A ( Figures 7C and 7D) . Foci of γ-H2AX can also be induced by factors other than ionizing radiation, such as during the process of replication and therefore not all cells have similar numbers of γ-H2AX foci after equal radiation doses. 51 The effect of SMC1A suppression was more pronounced in DU145 cells ( Figures 7A and 7B ). This is also corroborated by our observation that higher surviving fractions after irradiation correlated with a lower number of residual γ-H2AX
foci in the prostate cancer cells and DSB repair was impaired in SMC1A shRNA cells, compared with NT shRNA cells.
Our data support that radiation promotes a phenotypic switch toward EMT and stem-like traits in prostate cancer cells which may cause relapse and resistance after radiation therapy. SMC1A is involved in overcoming the resistance of cancer cells to radiation treatment. Thus, SMC1A represents an attractive novel target for radio-sensitizing prostate cancer cells. Development of novel therapeutic agents that target SMC1A for the treatment of this highly aggressive neoplasm could be a novel strategy to manage radio-resistant, metastatic prostate cancer cells.
| DISCUSSION
Radiation therapy remains an important modality for primary as well as locally advanced prostate cancer patients. [7] [8] [9] [10] [11] [12] [13] However, radioresistance and relapse/recurrence of tumor remains a major clinical The cohesin protein structural maintenance of chromosome-1 (SMC1A) is one of the target substrate of ataxia-telangiectasia mutated (ATM) kinase, the key sensor of the DNA damage response along with p53, Nibrin (NBS1), and breast cancer 1 (BRCA1). 28, 29, [46] [47] [48] In response to ionizing radiation, ATM kinase is activated and phosphorylates SMC1A and it has been shown to be the only target of ATM whose phosphorylation directly affects cell survival as lack of other substrates of ATM including p53, NBS1, and BRCA1 has no significant effects on radiosensitivity. 28, 29 Loss of SMC1A phosphorylation abolishes the S-phase delay induced by radiation and leads to increased radiosensitivity. Moreover, the role of SMC1A in the cellular response to oxidative stress is also considered to be significant. [46] [47] [48] SMC1A is overexpressed in several malignancies and shown to be involved in the regulation of the EMT phenotype and stem cell pluripotency. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 
SMC1A, a member of cohesin known as nuclear protein has been found to be associated with cell membrane, microtubules, and centrosomes which may provide a basis for its additional role including cellular response to stress, tumor progression, and metastasis. SMC1A downregulation in prostate cancer cells could help in augmenting the radiosensitivity and could be useful in reversing intrinsic or acquired drug-resistance of cancer cells toward radiation and chemotherapy. 
